Skip to main content

Advertisement

SpringerLink
Log in

Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objective

To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy.

Methods

From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation therapy for T1c–T3b prostate cancer. The IPSS was assessed preimplant and at 1, 6, 12, 24, 36, and 48 months after treatment. Clinical and treatment-related factors were assessed for correlations with the IPSS increase.

Results

The mean preimplant IPSS was 7.4, with the greatest mean score of 16.0 at 1 month. At 6 months, the mean total IPSS had decreased to 11.5, but it was still statistically significantly greater than that at baseline (<0.001). At 12 months, the IPSS was decreased to 8.6, slightly greater than baseline (p = 0.001). The IPSS of 45.4 % (69/152) patients gradually returned to preimplant levels and that of 71.1 % (108/152) patients returned to within 3 points of the baseline at 24 months. At 24, 36, and 48 months after seed implantation, the IPSS was 8.6, 7.7, and 8.2, respectively, and none of these values differed statistically significantly from baseline (p > 0.05). Sixteen patients (3.1 %) showed AUR, and 11 patients required catheterization. On univariate and multivariate analyses, the IPSS increase was best predicted by lower preimplant IPSS.

Conclusion

In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 24 months. The IPSS increase was best predicted by lower preimplant IPSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR (2004) The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22(11):2141–2149

    Article  PubMed Central  PubMed  Google Scholar 

  2. Zelefsky MJ, Worman M, Cohen GN, Pei X, Kollmeier M, Yamada J, Cox B, Zhang Z, Bieniek E, Dauer L, Zaider M (2010) Real-time intraoperative computed tomography assessment of quality of permanent interstitial seed implantation for prostate cancer. Urology 76(5):1138–1142

    Article  PubMed Central  PubMed  Google Scholar 

  3. Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I (1983) Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 130(2):283–286

    CAS  PubMed  Google Scholar 

  4. Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA (2004) Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71(1):29–33

    Article  PubMed  Google Scholar 

  5. Chen AB, D’Amico AV, Neville BA, Earle CC (2006) Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 24(33):5298–5304

    Article  PubMed  Google Scholar 

  6. Ikeda T, Shinohara K (2009) Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review. Int J Urol 16(6):558–560

    Article  PubMed  Google Scholar 

  7. Han BH, Demel KC, Wallner K, Ellis W, Young L, Russell K (2001) Patient reported complications after prostate brachytherapy. J Urol 166(3):953–957

    Article  CAS  PubMed  Google Scholar 

  8. Terk MD, Stock RG, Stone NN (1998) Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160(4):1379–1382

    Article  CAS  PubMed  Google Scholar 

  9. Ohashi T, Yorozu A, Toya K, Saito S, Momma T (2006) Serial changes of international prostate symptom score following I-125 prostate brachytherapy. Int J Clin Oncol 11(4):320–325

    Article  PubMed  Google Scholar 

  10. Tanaka N, Fujimoto K, Hirao Y, Asakawa I, Hasegawa M, Konishi N (2009) Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Urology 74(2):407–411

    Article  PubMed  Google Scholar 

  11. Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, Gould K (2007) Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 82(1):46–49

    Article  PubMed  Google Scholar 

  12. Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. J Urol 148(5):1549–1557 (discussion 1564)

    CAS  PubMed  Google Scholar 

  13. Merrick GS, Butler WM, Lief JH, Dorsey AT (2000) Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47(1):121–128

    Article  CAS  PubMed  Google Scholar 

  14. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M (2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52(2):453–460

    Article  PubMed  Google Scholar 

  15. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S (1999) Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45(1):59–67

    Article  CAS  PubMed  Google Scholar 

  16. Lee WR, McQuellon RP, Harris-Henderson K, Case LD, McCullough DL (2000) A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 46(1):77–81

    Article  CAS  PubMed  Google Scholar 

  17. Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM (2004) Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. Radiother Oncol 73(1):33–38

    Article  PubMed  Google Scholar 

  18. Aaltomaa SH, Kataja VV, Lahtinen T, Palmgren JE, Forsell T (2009) Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy–morbidity and outcome results. Radiother Oncol 91(2):213–216

    Article  PubMed  Google Scholar 

  19. Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, Lapointe V, Halperin R, Morris WJ (2009) Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 73(4):1023–1032

    Article  PubMed  Google Scholar 

  20. Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69(2):338–342

    Article  PubMed  Google Scholar 

  21. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW (2002) Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 60(4):650–655

    Article  PubMed  Google Scholar 

  22. Salem N, Simonian-Sauve M, Rosello R, Alzieu C, Gravis G, Maraninchi D, Bladou F (2003) Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study. Radiother Oncol 66(2):159–165

    Article  PubMed  Google Scholar 

  23. Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W (2002) I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 8(1):67–73

    Article  PubMed  Google Scholar 

  24. Kelly K, Swindell R, Routledge J, Burns M, Logue JP, Wylie JP (2006) Prediction of urinary symptoms after 125iodine prostate brachytherapy. Clin Oncol (R Coll Radiol) 18(4):326–332

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was partly supported by Pfizer Asia Urology Preceptorship Program. The authors wish to acknowledge and thank all of the people who helped make this study possible, and in particular, the doctors in the Department of Urology, University of California at San Francisco.

Conflict of interest

None of the contributing authors have any conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, 1600 Divisadero St, Box 1695, San Francisco, CA, 94143-1695, USA

    Xuesong Li, Matthew R. Cooperberg, Jared M. Whitson, Tom F. Lue & Katsuto Shinohara

  2. Department of Urology, National Urological Cancer Center, Institute of Urology, Peking University First Hospital, Peking University, No. 8 Xishiku St, Xicheng District, Beijing, 100034, China

    Xuesong Li, Dong Fang & Liqun Zhou

Authors
  1. Xuesong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew R. Cooperberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jared M. Whitson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tom F. Lue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liqun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katsuto Shinohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xuesong Li or Matthew R. Cooperberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, X., Fang, D., Cooperberg, M.R. et al. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol 32, 1061–1066 (2014). https://doi.org/10.1007/s00345-013-1188-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-013-1188-y

Keywords

Search

Navigation